GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioventix PLC (LSE:BVXP) » Definitions » EV-to-EBIT

Bioventix (LSE:BVXP) EV-to-EBIT : 20.60 (As of May. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Bioventix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bioventix's Enterprise Value is £222.86 Mil. Bioventix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £10.82 Mil. Therefore, Bioventix's EV-to-EBIT for today is 20.60.

The historical rank and industry rank for Bioventix's EV-to-EBIT or its related term are showing as below:

LSE:BVXP' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.06   Med: 21   Max: 31.27
Current: 20.6

During the past 13 years, the highest EV-to-EBIT of Bioventix was 31.27. The lowest was 10.06. And the median was 21.00.

LSE:BVXP's EV-to-EBIT is ranked worse than
67.43% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs LSE:BVXP: 20.60

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bioventix's Enterprise Value for the quarter that ended in Dec. 2023 was £222.27 Mil. Bioventix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £10.82 Mil. Bioventix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.87%.


Bioventix EV-to-EBIT Historical Data

The historical data trend for Bioventix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioventix EV-to-EBIT Chart

Bioventix Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.43 26.07 24.68 18.71 19.27

Bioventix Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 18.71 - 19.27 -

Competitive Comparison of Bioventix's EV-to-EBIT

For the Biotechnology subindustry, Bioventix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioventix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioventix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioventix's EV-to-EBIT falls into.



Bioventix EV-to-EBIT Calculation

Bioventix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=222.855/10.818
=20.60

Bioventix's current Enterprise Value is £222.86 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioventix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £10.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventix  (LSE:BVXP) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bioventix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=10.818/222.266
=4.87 %

Bioventix's Enterprise Value for the quarter that ended in Dec. 2023 was £222.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bioventix's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £10.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioventix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bioventix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioventix (LSE:BVXP) Business Description

Traded in Other Exchanges
Address
East Street, 7 Romans Business Park, Farnham, Surrey, GBR, GU9 7SX
Bioventix PLC is a biotechnology company based in the United Kingdom. It specializes in the creation and supply of high-affinity sheep monoclonal antibodies and clinical diagnostics and drug abuse testing. The company's portfolio of products includes drugs that are applicable in the areas of cardiology, fertility, infectious diseases, Thyroid, and vitamin D disorder among others.

Bioventix (LSE:BVXP) Headlines

No Headlines